Spondyloarthritis & psoriatic arthritis
Persistence of remission after lengthening of golimumab in inflammatory joint diseases
Authors' conclusion
Results show that golimumab lengthening is safe and successfully maintains remission.
Study context
- Population
- Patients with rheumatoid arthritis (RA), psoriatic arthritis (PsA), ankylosing spondylitis (AS) and juvenile idiopathic arthritis (JIA) treated with golimumab; all with active disease at baseline34 AS, 33 PsA, 9 RA, 4 JIA
- Participants
- 80 patients
- Exposure
- Lengthened golimumab injection interval vs standard dose in patients in remission
- Lengthenedn = 22
- Standard dosen = 38reference
- Outcome
- Remission persistency after lengthening the time between golimumab injections
- Follow-up
- T2 (12 months after lengthening started)
Main finding
As reported in the abstract
Remission persistence after lengthening of golimumab injection interval
Patients who started tapering at T1 in remission at T2: 20/22 pts
91%
Observational data: associations, not effects.
Further findings
- Flare with switch/swap of bDMARD — Standard dose
- 4 events
BASDAI at T1 in patients who lost vs kept remission at T2
- BASDAI higher at T1 in patients who lost remission at T2: 2.2 (SD 0.28) vs 0.58 (SD 0.47)
- P < 0.001
Remission after flare
- Patients who flared recovered remission once taken back to a 28-day interval
Flare with switch/swap of bDMARD
- Difference in retention rate vs reduced dose not significant
Remission at T1
- Patients reaching remission at T1
- 60/80
Original publication
Persistence of remission after lengthening of golimumab in inflammatory joint diseases. Clin Exp Rheumatol. Published 6 February 2022. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →